Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Special issues
    • Subject collections
    • Sign up for alerts
  • About us
    • About Development
    • About the Node
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contacts
    • Contacts
    • Subscriptions
    • Advertising
    • Feedback
    • For library administrators
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in
  • Log out

Search

  • Advanced search
Development
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Development

  • Log in
Advanced search

RSS  Twitter  Facebook  YouTube 

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Special issues
    • Subject collections
    • Sign up for alerts
  • About us
    • About Development
    • About the Node
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contacts
    • Contacts
    • Subscriptions
    • Advertising
    • Feedback
    • For library administrators
Review
MEF2: a central regulator of diverse developmental programs
Matthew J. Potthoff, Eric N. Olson
Development 2007 134: 4131-4140; doi: 10.1242/dev.008367
Matthew J. Potthoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric N. Olson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & tables
  • Info & metrics
  • PDF
Loading

Summary

The myocyte enhancer factor 2 (MEF2) transcription factor acts as a lynchpin in the transcriptional circuits that control cell differentiation and organogenesis. The spectrum of genes activated by MEF2 in different cell types depends on extracellular signaling and on co-factor interactions that modulate MEF2 activity. Recent studies have revealed MEF2 to form an intimate partnership with class IIa histone deacetylases, which together function as a point of convergence of multiple epigenetic regulatory mechanisms. We review the myriad roles of MEF2 in development and the mechanisms through which it couples developmental, physiological and pathological signals with programs of cell-specific transcription.

Introduction

The formation of specialized cell types and their integration into different tissues and organs during development requires the interpretation of extracellular signals by components of the transcriptional apparatus and through the subsequent activation of cascades of regulatory and structural genes by combinations of widely expressed and cell type-restricted transcription factors. The myocyte enhancer factor 2 (MEF2) transcription factor plays central roles in the transmission of extracellular signals to the genome and in the activation of the genetic programs that control cell differentiation, proliferation, morphogenesis, survival and apoptosis of a wide range of cell types.

Recent studies in mice and fruit flies have revealed upstream signaling systems that control MEF2 expression and activity, and downstream effector genes that mediate the actions of MEF2 throughout development, as well as in adult tissues. These studies point to MEF2 having a central role as a mediator of epigenetic regulatory mechanisms that involve changes in chromatin configurations and the modulation of microRNAs. Here we review the mechanisms that govern MEF2 activity and discuss commonalities in the functions of MEF2 as a regulator of differentiation of diverse cell types. The requirement of MEF2 for the differentiation of seemingly unrelated cell types from multiple lineages points to MEF2 being a key component of the regulatory codes that are required for metazoan development.

The MEF2 family

MEF2 proteins belong to the evolutionarily ancient MADS (MCM1, agamous, deficiens, SRF) family of transcription factors (Shore and Sharrocks, 1995). Saccharomyces cerevisiae, Drosophila and Caenorhabditis elegans possess a single Mef2 gene, whereas vertebrates have four - Mef2a, b, c and d. The N-termini of MEF2 factors contain a highly conserved MADS-box and an immediately adjacent motif termed the MEF2 domain (Fig. 1), which together mediate dimerization, DNA binding, and co-factor interactions (Black and Olson, 1998; McKinsey et al., 2002a). The C-terminal regions of MEF2 proteins, which function as transcriptional activation domains, are subject to complex patterns of alternative splicing (Martin et al., 1994) and are divergent among family members (Fig. 1).

MEF2 proteins bind to the consensus DNA sequence YTA(A/T)4TAR as homo- or heterodimers (Andres et al., 1995; Fickett, 1996; Gossett et al., 1989; Molkentin and Olson, 1996; Pollock and Treisman, 1991; Yu et al., 1992). Although MEF2 is a transcriptional activator, it relies on the recruitment of, and cooperation with, other transcription factors to drive the expression of its target genes. In addition, complex transcriptional, translational and post-translational mechanisms govern the functions of MEF2.

Yeast MEF2, referred to as Rlm1, binds the same DNA sequence as the vertebrate MEF2 proteins and functions as a downstream effector of the mitogen-activated protein (MAP) kinase pathway (Dodou and Treisman, 1997). Rlm1 regulates a cadre of genes that encode proteins involved in cell wall biosynthesis.

The four vertebrate Mef2 genes display distinct, but overlapping, temporal and spatial expression patterns in embryonic and adult tissues, with highest expression in striated muscles and brain (Edmondson et al., 1994). However, in vertebrates, MEF2 is also expressed in lymphocytes, neural crest, smooth muscle, endothelium and bone (Arnold et al., 2007; Edmondson et al., 1994), and several reports claim that MEF2 proteins are ubiquitous (Black et al., 1997; Martin et al., 1993; McDermott et al., 1993; Pollock and Treisman, 1991; Yu et al., 1992). The expression of MEF2 proteins in many cell types, including in neurons, chondrocytes and muscle (cardiac, skeletal, and smooth), occurs concomitantly with the activation of their differentiation programs, and the balance between the transcription-activating functions of MEF2 and the repressive functions of class IIa histone deacetylases (HDACs) dictates the development of these tissues (Fig. 2) (Arnold et al., 2007; Chang et al., 2004; Chang et al., 2006; Lu et al., 2000; Verzi et al., 2007; Youn and Liu, 2000).

In adult tissues, MEF2 proteins act as a nodal point for stress-response and remodeling programs (for example, during cardiac hypertrophy and fiber-type switching in cardiac and skeletal muscle, respectively) (Potthoff et al., 2007b; Zhang et al., 2002). MEF2 proteins have also been implicated in cell survival, apoptosis and proliferation. In each of these settings, the spectrum of target genes activated by MEF2 depends on the specific post-translational modifications MEF2 undergoes and on its interaction with its co-factors.

Signaling to MEF2

MEF2 proteins serve as endpoints for multiple signaling pathways and thereby confer signal-responsiveness to downstream target genes (Fig. 2). MAP kinase signaling pathways converge on MEF2 factors in organisms ranging from yeast to humans (Dodou and Treisman, 1997; Han et al., 1997; Kato et al., 1997). Phosphorylation of the transcription activation domain of MEF2 by MAP kinases augments its transcriptional activity, and the MAP kinase ERK5 (also known as BMK1 and MAPK7) serves as a MEF2 coactivator through its signal-dependent direct association with the MEF2 MADS domain (Yang et al., 1998).

    Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Sequence conservation of MEF2. The percentage amino acid identity within the MADS, MEF2 and transcriptional activation domains of different MEF2 proteins from various organisms relative to human (h) MEF2A. N-termini are to the left.

    Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

MEF2 as a central regulator of differentiation and signal responsiveness. MAP kinase signaling activates MEF2. Calcium-dependent signals also activate MEF2 by stimulating calcium-dependent kinases that phosphorylate class II HDACs, thereby promoting their dissociation from MEF2 and derepressing MEF2 target genes. MEF2 recruits numerous co-factors to drive the differentiation of the various cell types shown. Although MAPK and HDAC signaling pathways have been implicated in the modulation of numerous MEF2-dependent developmental programs, these signaling pathways have not yet been shown to operate in all the cell types under MEF2 control.

Calcium signaling pathways also modulate MEF2 activity through multiple mechanisms. In this regard, the activity of MEF2 is tightly governed by class IIa HDACs, which associate with the MADS domain and promote the formation of multiprotein repressive complexes on MEF2-dependent genes (Bertos et al., 2001; de Ruijter et al., 2003; McKinsey et al., 2001; McKinsey et al., 2002a; McKinsey et al., 2002b) (Fig. 2), such as myogenin (Cheng et al., 1993; Edmondson et al., 1992; Malik et al., 1995; Yee and Rigby, 1993), myoglobin (Bassel-Duby et al., 1992) and matrix metalloproteinase 10 (Mmp10) (Chang et al., 2006). Numerous calcium-regulated protein kinases, including protein kinase D (PKD) and calcium calmodulin-dependent protein kinases (CaMKs) phosphorylate class II HDACs on a series of conserved serine residues. This phosphorylation promotes the nuclear-to-cytoplasmic shuttling of these HDACs and the subsequent activation of MEF2 (McKinsey and Olson, 2005; Zhang et al., 2002). The regulated phosphorylation of class II HDACs thus provides a mechanism for the modulation of MEF2 target genes in response to physiological and pathological signaling.

MEF2: a central regulator of Drosophila myogenesis

MEF2 was first identified as a regulator of muscle gene expression (Gossett et al., 1989). The central role of MEF2 in orchestrating muscle development has been delineated most thoroughly in Drosophila. The single Mef2 gene in Drosophila is expressed in early mesoderm and subsequently in different muscle cell lineages, where it is required for myoblast differentiation (Bour et al., 1995; Lilly et al., 1995; Ranganayakulu et al., 1995) (Fig. 3). A complex array of enhancers governs the transcription of Mef2 in different cell types during Drosophila development. Mef2 expression within the early mesoderm (Fig. 3A) requires a mesodermal enhancer that is directly activated by Twist (Cripps et al., 1998), a bHLH transcription factor required for mesoderm formation (Simpson, 1983). Twist and the zinc-finger transcription factor Lame duck act through separate enhancers to control Mef2 transcription in specific sets of somatic muscle cells later in development (Fig. 3B) (Duan et al., 2001). MAD and Medea, downstream effectors of Decapentaplegic (DPP) signaling, also act directly on an Mef2 enhancer to control its expression in the somatic muscle lineage (Nguyen and Xu, 1998). In addition, Mef2 maintains its own transcription late in the muscle differentiation pathway by activating a distal Mef2-dependent autoregulatory enhancer (Cripps et al., 2004).

Within the cardiac lineage (Fig. 3C), the homeodomain protein Tinman directs Mef2 transcription through a cardiac-specific enhancer that also contains essential binding sites for GATA factors (Cripps and Olson, 1998; Gajewski et al., 1997). Intriguingly, a mutation of the GATA sites switches the cell-type specificity of the enhancer from cardial to pericardial cells (Gajewski et al., 1998).

In Mef2 mutant Drosophila embryos, somatic muscle founder cells are appropriately specified, but there is a complete block in myoblast fusion and in the expression of muscle differentiation markers (Bour et al., 1995; Lilly et al., 1995; Prokop et al., 1996; Ranganayakulu et al., 1995). Similarly, cardiac cells within the dorsal vessel, which functions as a heart, are patterned properly in Mef2 mutant embryos, but cardiac contractile protein genes are not expressed.

Several approaches have been taken to identify MEF2 target genes in Drosophila. The use of chromatin immunoprecipitation (ChIP), followed by microarray analysis (ChIP on chip) on a tiling array that covers ∼50% of the Drosophila genome, identified more than 200 direct target genes of MEF2 and over 650 regions of the genome that are bound by MEF2, highlighting the central role of MEF2 in the transcriptional hierarchy for myogenesis (Sandmann et al., 2006). Similar findings were made by an independent study that combined ChIP with spotted DNA microarrays that contain in-silico predicted cis-regulatory module targets (the so-called ChEST strategy) (Junion et al., 2005).

MEF2 exhibits three temporal patterns of enhancer binding during Drosophila muscle development. Although MEF2 is present at high levels early in development, it does not bind the enhancers of muscle differentiation genes until later in development, indicating the existence of mechanisms that govern target gene recognition by MEF2 (Sandmann et al., 2006). Twist, the central bHLH protein partner for MEF2 in the somatic muscle lineage in Drosophila (Cripps and Olson, 1998), binds with MEF2 to enhancers that are activated early in the mesodermal and myogenic lineages (Sandmann et al., 2007).

    Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Roles of MEF2 in Drosophila muscle development. (A) In the early mesoderm, MEF2 expression is activated by Twist, and MEF2 regulates downstream genes involved in cell migration, signaling and founder cell identity. (B) During differentiation of the somatic muscle lineage, Lame duck (LMD) activates MEF2 expression in a subset of muscle cells. DPP also regulates MEF2 expression via Twist and MAD/Medea. During late myogenesis, MEF2 autoactivates its own expression. MEF2 regulates hundreds of genes involved in contractility, neuromuscular junction formation, myoblast fusion, ion transport and metabolism. (C) In the developing dorsal vessel, MEF2 is regulated by GATA factors, Tinman, and by an as yet unidentified bHLH factor. MEF2 is essential for the expression of genes involved in cardiac contractility.

Drosophila MEF2 also regulates a striking number of genes that encode components of the Notch-Delta pathway, as well as of the Wingless (WNT), Hedgehog (HH), Fibroblast growth factor (FGF) and Epidermal growth factor (EGF) signaling pathways, which are involved in specifying the identities of somatic muscle founder cells (Sandmann et al., 2006). This type of function of MEF2 in the early stages of myogenesis coincides with the early, Twist-dependent phase of MEF2 expression and its regulation of genes in the early mesoderm (Taylor, 2000; Ruiz-Gomez et al., 2002).

Unexpectedly, MEF2 also regulates the enhancers of muscle identity genes, suggesting that it contributes to the robustness of myogenesis (Sandmann et al., 2006). At later stages of myogenesis, MEF2 regulates genes that are involved in muscle attachment, neuromuscular junction (NMJ) formation, ion transport, channel activity, metabolism and contractility (Sandmann et al., 2007) (Fig. 3B). These studies suggest that MEF2 regulates most, if not all, muscle genes, not just those encoding `late' structural proteins of differentiated muscle, and thereby acts as a central regulator of myogenesis.

The ectopic expression of MEF2 in the epidermis of Drosophila results in the activation of skeletal muscle genes, such as Tropomyosin 1 (Tm1), whereas ectopic expression of MEF2 in the nervous system does not activate these genes (Lin, M. H. et al., 1997), suggesting that the epidermis expresses a co-factor that cooperates with MEF2 to activate the muscle gene program. In this regard, a novel PAR-domain bZIP transcription factor, PDP1, which is expressed in cell types that are susceptible to MEF2-dependent muscle gene activation, has been shown to cooperate with MEF2 to activate muscle gene expression (Lin, S. C. et al., 1997).

In contrast to Drosophila, which contains a single Mef2 gene, elucidation of the functions of mammalian Mef2 genes has been comparably more difficult owing to the existence of four related genes that have overlapping expression patterns. In vertebrates, loss-of-function mutations frequently reveal only a subset of MEF2 functions in tissues in which the genes do not function redundantly. By generating conditional alleles of the different Mef2 genes, we are now beginning to ascertain the importance of specific MEF2 proteins in various tissues through their combinatorial deletion (Arnold et al., 2007). Alternatively, the overexpression of chimeric MEF2 fusion proteins, such as the super-active MEF2-VP16 or super-repressive MEF2-engrailed, has been used to elucidate MEF2 function in different tissues while bypassing functional redundancy (Arnold et al., 2007; Karamboulas et al., 2006; Potthoff et al., 2007b).

MEF2 control of vertebrate skeletal muscle differentiation

Vertebrate skeletal muscle differentiation is regulated by the cooperative interactions of myogenic transcription factors with MEF2, and by signaling pathways that regulate MEF2 activity (Fig. 4). MEF2 factors alone do not possess myogenic activity but, in combination with bHLH transcription factors, drive and amplify the myogenic differentiation program (Molkentin et al., 1995; Wang et al., 2001). MEF2 also interacts with additional transcription factors that are required for proper muscle development. For example, the mastermind-like protein 1, MAML1, was recently shown to interact with MEF2C and to mediate crosstalk between Notch signaling and MEF2 in the regulation of myogenic differentiation (Shen et al., 2006). MEF2 has also been implicated in regulating skeletal myocyte survival through a CREB-dependent pathway (Berdeaux et al., 2007).

In addition to regulating numerous muscle structural genes, vertebrate MEF2 proteins regulate the expression of myogenic bHLH genes, such as myogenin, as well as other genes that encode transcription factors, thereby providing a positive feed-forward loop that perpetuates and amplifies the decision to differentiate (Cheng et al., 1993; Edmondson et al., 1992; Molkentin and Olson, 1996; Tapscott, 2005; Yee and Rigby, 1993). MEF2C has also been shown to positively regulate its own expression during mouse embryogenesis (Wang et al., 2001), consistent with the autoregulatory activity of Drosophila MEF2 (Cripps et al., 2004). Moreover, MEF2C activates the expression of the class IIa HDAC, HDAC9, thereby creating a negative-feedback loop that modulates and restrains MEF2 from excessive activity (Haberland et al., 2007) (Fig. 4). This type of negative-feedback loop also confers signal responsiveness to MEF2-dependent gene programs through the regulated phosphorylation of class IIa HDACs.

    Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

MEF2 and mammalian skeletal myogenesis. Upstream inductive signals activate the expression of MYOD and MYF5, which activate the expression of myogenin in skeletal myocytes. Myogenin activates MEF2 expression, which feeds back on the myogenin promoter to amplify and maintain its expression. Myogenin and MEF2 also autoregulate their own promoters. MEF2, together with myogenic bHLH factors, activates genes involved in muscle differentiation. In addition, MEF2 activates HDAC9 expression, providing a negative-feedback loop that can be modulated by upstream signals that regulate HDAC9 phosphorylation. MEF2 also regulates the expression of the microRNA miR-1, which represses HDAC4 translation, thereby providing a positive-feedback loop for myogenesis.

MEF2 establishes an additional level of myogenic regulation by regulating the expression of microRNAs (miRs), such as miR-1 and miR-133 (Sokol and Ambros, 2005; Zhao et al., 2005), that post-transcriptionally repress gene expression by binding the 3′ untranslated regions of mRNA targets and disrupting mRNA translation and stability (He and Hannon, 2004). Recently, several microRNAs were identified that affect skeletal muscle differentiation and proliferation (Boutz et al., 2007; Chen et al., 2006; Kim et al., 2006; Rao et al., 2006). Interestingly, miR-1 has been shown to target class II HDACs (such as HDAC4) (Chen et al., 2006) to establish a positive feed-forward mechanism for MEF2 activation and skeletal muscle differentiation (Fig. 4). This form of regulation, which enhances MEF2 activity, would oppose the direct activation of HDAC9 expression by MEF2, which represses MEF2 activity, illustrating the multifaceted mechanisms that exist to modulate MEF2. Presumably, these different regulatory loops are differentially controlled during various stages of skeletal muscle development and postnatal muscle remodeling.

Despite extensive studies of MEF2 in skeletal muscle in vitro, relatively little is known about the roles of MEF2 proteins in vertebrate skeletal muscle in vivo. During mouse embryogenesis, Mef2c is the first Mef2 gene to be expressed in the somite myotome (∼E9.0), with Mef2a and Mef2d expressed about a day later (Edmondson et al., 1994). Global deletion of Mef2a or Mef2d has little or no effect on skeletal muscle development (Potthoff et al., 2007a; Potthoff et al., 2007b). Since Mef2c-null mice die around E9.5 (Lin, Q. et al., 1997), its role in skeletal muscle was not examined until recently. Skeletal muscle deficient in Mef2c differentiates and forms myofibers during embryogenesis (Potthoff et al., 2007a; Potthoff et al., 2007b). However, on a C57BL/6 mixed genetic background, myofibers from mice with a skeletal muscle-specific deletion of Mef2c rapidly deteriorate after birth owing to the occurrence of disorganized sarcomeres and to the loss of integrity of the sarcomere M-line (Potthoff et al., 2007a). Interestingly, similar results have been observed in zebrafish following the combined knockdown of mef2c and mef2d (Hinits and Hughes, 2007). Notably, the muscle-specific overexpression of a super-active MEF2 protein in mice does not drive premature skeletal muscle differentiation (Potthoff et al., 2007b), consistent with previous in vitro studies that have demonstrated that MEF2 is not sufficient to drive skeletal muscle differentiation (Molkentin et al., 1995). These results reveal a key role for MEF2 proteins in the maintenance of sarcomere integrity and in the postnatal maturation of skeletal muscle.

Control of vertebrate heart development by MEF2

MEF2 regulates the expression of numerous cardiac structural and contractile proteins. Cardiac-specific overexpression of the repressive MEF2C-engrailed fusion protein under the control of the Nkx2-5 enhancer (∼E7.5) is sufficient to inhibit cardiomyocyte differentiation in vitro and in vivo. Moreover, the overexpression of MEF2C-engrailed downregulates the expression of GATA and NKX proteins in cardiomyocytes (Karamboulas et al., 2006), confirming the role of MEF2 as a regulator of the other core cardiac transcription factors that are required for cardiomyocyte differentiation.

Notably, cardiomyocyte development can still occur despite the loss of individual vertebrate MEF2 proteins. In the mouse and chick, MEF2C is the first MEF2 factor to be expressed, appearing initially in mesodermal precursors that give rise to the heart (Edmondson et al., 1994). Shortly thereafter, the other Mef2 transcripts are expressed. Mef2c-null mice die around E9.5 from cardiac looping defects (Lin, Q. et al., 1997), and Mef2a-null mice exhibit perinatal lethality from an array of cardiovascular defects (Naya et al., 2002). By contrast, Mef2d-null mice appear normal (Arnold et al., 2007). Although Mef2c-null mice exhibit early embryonic lethality, cardiomyocytes are still able to differentiate prior to the looping defects that occur (Lin, Q. et al., 1997). Interestingly, mice with a cardiac-specific deletion of Mef2c, which occurs at around E9.5 (αMyHC-cre), are viable (Vong et al., 2005), which demonstrates that Mef2c is dispensable in the heart after cardiac looping, probably owing to it being compensated for by other MEF2 factors.

    Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Control of anterior heart field development by MEF2C. MEF2C expression in the anterior heart field is controlled by GATA4, ISL1 and FOXH1, together with NKX2-5. MEF2C directly activates the expression of BOP, which is required for expression of HAND2, an essential regulator of anterior heart field development. Solid lines indicate direct regulatory interactions and dotted lines indicate regulatory interactions for which the underlying mechanism has not yet been defined.

    Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Control of neural crest development by MEF2C. Signaling by endothelin 1 (EDN1) through the ET-A receptor (EDNRA) activates MEF2C expression in the neural crest. MEF2C directly activates the expression of DLX5 and DLX6, which regulate the expression of HAND2. Together, these factors regulate the expression of genes required for craniofacial development.

Recent studies indicate that MEF2C is a nodal point in the development of the anterior heart field, which gives rise to the outflow tract and right ventricle of the heart (Black, 2007) (Fig. 5). In Mef2c mutant embryos, derivatives of the anterior heart field fail to form (Lin, Q. et al., 1997). Activation of Mef2c transcription in the anterior heart field is controlled by at least two separate enhancers: one that is activated directly by the forkhead DNA-binding transcription factor FOXH1, together with NKX2-5, which also confers TGF-β responsiveness to Mef2c (von Both et al., 2004); and a second enhancer that serves as a direct target of GATA4 and the LIM-homeodomain transcription factor ISL1, which is itself required for the formation of the anterior heart field (Dodou et al., 2004; Cai et al., 2003). Expression of the transcriptional repressor and putative histone methyltransferase BOP (also known as SMYD1) in the anterior heart field is controlled by the direct activation of an upstream enhancer by MEF2C (Phan et al., 2005), and the cardiac defects seen in Bop mutant embryos partially phenocopy those of Mef2c mutants, suggesting that Bop is an essential downstream mediator of the actions of MEF2C in the anterior heart field (Gottlieb et al., 2002). The bHLH transcription factor HAND2 appears to be a key target of BOP regulation, although the mechanistic basis for this regulation has not been resolved.

Control of neural crest development by MEF2

Neural crest cells are multipotent, migratory cells that originate between the dorsal neural tube and epidermis of the embryo (Knecht and Bronner-Fraser, 2002; Trainor, 2005). In response to specific signaling cues, neural crest cells undergo an epithelial-to-mesenchymal transition, and then migrate to different parts of the embryo to give rise to a variety of cell types, including neurons, skeletal and smooth muscle, chondrocytes, osteocytes, melanocytes, hormone-producing cells, and many more (Knecht and Bronner-Fraser, 2002). Loss of Mef2c in neural crest cells results in craniofacial defects and neonatal lethality caused by an upper airway obstruction (Verzi et al., 2007); in zebrafish, loss of mef2ca produces similar craniofacial defects (Miller et al., 2007). MEF2C directly activates the expression of the homeodomain transcription factors DLX5 and DLX6, two transcription factors that are necessary for craniofacial development, and MEF2C acts synergistically with these factors to direct craniofacial development (Miller et al., 2007; Verzi et al., 2007) (Fig. 6).

The peptide hormone endothelin controls a diverse array of developmental processes, including neural crest migration and differentiation during craniofacial development (Clouthier et al., 1998; Kurihara et al., 1994). DLX6 and the transcription factor HAND2 are important regulators of branchial arch development and require endothelin signaling for their expression (Charitè et al., 2001; Clouthier et al., 2000; Thomas et al., 1998). Interestingly, aspects of endothelin signaling in zebrafish require Mef2, including activation of the endothelin target genes hand2, dlx5 and dlx6 (Miller et al., 2007) (Fig. 6). Therefore, MEF2 plays a crucial role in neural crest development by activating the expression of endothelin signaling-dependent transcription factors that are required for proper development.

Control of bone development by MEF2

During embryonic development, bones develop through intramembranous or endochondral ossification. Endochondral ossification involves a cartilaginous intermediate, whereas intramembranous ossification occurs through the direct conversion of mesenchymal tissue into bone (Hall and Miyake, 1995). During endochondral ossification, mesenchymal precursor cells become committed to cartilage cells, forming a template for future bone. These committed mesenchymal cells differentiate into chondrocytes, proliferate rapidly to form a template for osteoblasts (committed bone precursor cells), secrete a cartilage-specific extracellular matrix, and then stop dividing and undergo hypertrophy (Bruder and Caplan, 1989). Signaling coordinated by Indian hedgehog (IHH) and parathyroid hormone-related peptide (PTHrP; also known as PTHLH) regulates the hypertrophy of chondrocytes, which is necessary for bone vascularization, osteoblast differentiation and endochondral ossification. IHH produced by prehypertrophic chondrocytes induces the expression of PTHrP, which regulates the rate at which chondrocytes undergo hypertrophy (Karaplis et al., 1994; Lanske et al., 1996; St-Jacques et al., 1999; Vortkamp et al., 1996; Weir et al., 1996).

    Fig. 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 7.

Regulation of bone development by MEF2. (A) High-magnification frontal view of Hematoxylin and Eosin-stained sections of mouse sternum. Left, wild-type trabeculated bone. MEF2C KO, chondrocyte-specific deletion of a conditional Mef2c allele, which results in a lack of bone owing to failure in chondrocyte hypertrophy. MEF2-engrailed super-repressor, when expressed in the cartilage of transgenic mice, also prevents ossification, whereas expression of a MEF2-VP16 super-activator results in the formation of excessive bone. (B) MEF2C and MEF2D promote chondrocyte hypertrophy and vascularization of developing bones by activating a network of transcription factors and signaling molecules involved in bone development. HDAC4 imposes negative control over the network by repressing the activity of MEF2 [adapted from Arnold et al. (Arnold et al., 2007)]. IHH, Indian hedgehog; PTHrP, parathyroid hormone-related peptide; RUNX2, runt related transcription factor 2.

Recently, MEF2 proteins were shown to be necessary and sufficient to drive chondrocyte hypertrophy (Arnold et al., 2007) (Fig. 7A). Interestingly, this function of MEF2 is tightly regulated by the opposing function of HDAC4 (Arnold et al., 2007; Vega et al., 2004). Genetic deletion of Hdac4 (Vega et al., 2004) or the chondrocyte-specific overexpression of a constitutively activated form of MEF2C - the MEF2C-VP16 fusion protein - in mice is sufficient to drive premature bone formation (Arnold et al., 2007) (Fig. 7A). Conversely, the genetic deletion of Mef2c, or the overexpression of a MEF2-engrailed repressor in mouse chondrocytes, prevents chondrocyte hypertrophy and endochondral ossification (Arnold et al., 2007) (Fig. 7A). MEF2 functions, at least in part, by directly activating collagen 10a1 (Col10a1) expression, a specific marker of chondrocyte hypertrophy, and Runx2, a transcription factor necessary for chondrocyte hypertrophy (Arnold et al., 2007) (Fig. 7B). Undoubtedly, however, there are additional downstream targets and upstream regulators of MEF2 in developing chondrocytes that remain to be defined.

Control of vascular integrity by MEF2

The development of the vasculature occurs through two stages, termed vasculogenesis and angiogenesis. Vasculogenesis is the de novo formation of blood vessels from mesodermal progenitor cells, and angiogenesis is the expansion of a capillary plexus by the formation of additional branches from pre-existing vessels (Patan, 2000). MEF2 proteins are expressed in developing endothelial and smooth muscle cells (Lin et al., 1998) and are required for vascular development and for the maintenance of vascular integrity. Mef2c expression in the developing endothelium is controlled by a conserved endothelial-specific enhancer that binds ETS-family factors and drives expression as early as E8.5 in all endothelial cells of the mouse embryo and yolk sac (De Val et al., 2004). Endothelial cells are specified and differentiated in Mef2c-null mice, but they are unable to organize properly (Lin et al., 1998).

MEF2 proteins have been implicated in maintaining vascular integrity by promoting endothelial cell survival (Hayashi et al., 2004; Olson, 2004) (Fig. 8). The MAP kinase ERK5 is necessary for endothelial cell survival and proliferation; its conditional deletion from endothelial cells in mice results in vascular death and embryonic lethality (at E9.5-10.5) due to apoptosis and a failure of endothelial cells to proliferate (Hayashi et al., 2004). The introduction of MEF2C-VP16 into ERK5-deficient endothelial cells is sufficient to partially protect the cells from apoptosis, whereas the removal of ERK5 from endothelial cells eliminates the serum-stimulated activation of MEF2 in these cells (Hayashi et al., 2004).

Recently, we demonstrated an unexpected role for MEF2-HDAC signaling in the maintenance of vascular integrity (Fig. 8). HDAC7 is expressed specifically in endothelial cells during development, and global deletion of Hdac7 results in embryonic lethality due to blood vessel rupture caused by defects in cell-cell adhesion, a phenotype that is recapitulated by the endothelial-specific deletion of Hdac7 (Chang et al., 2006). Knockdown of HDAC7 in human endothelial cells in vitro results in a similar loss in cell adhesion, accompanied by upregulation of MMP10, a secreted endoproteinase that degrades the extracellular matrix, and downregulation of its inhibitor, tissue inhibitor of metalloproteinase 1 (TIMP1). MEF2 proteins directly activate the expression of MMP10, and HDAC7 is sufficient to repress this activation (Chang et al., 2006).

Abnormalities in growth and integrity of the vascular endothelium lead to a variety of cardiovascular disorders (for example, atherosclerosis and aneuryisms). During development, MEF2 may be involved in angiogenesis by promoting cell survival (Hayashi et al., 2004) and vascular remodeling (Chang et al., 2006). In response to stress signals (for example, oxidative or fluid shear stress), MEF2 activation may actually promote vascular remodeling at the site of injury. In this regard, ERK5 has been demonstrated to be atheroprotective, as it displays increased activation in response to fluid shear stress and oxidative stress (Pi et al., 2004). Therefore, if MEF2 becomes activated at local sites of injury, which results in blood vessel remodeling, then removal of MEF2 repression by deletion of Hdac7 might explain the global vascular rupture that is seen in Hdac7-null embryos.

    Fig. 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 8.

MEF2 functions in the endothelium. During embryogenesis, MEF2C expression in the endothelium is dependent on ETS factors, which bind an endothelial cell-specific enhancer. MEF2 activity is also modulated in the endothelium by survival factors, which act through the MAP kinase pathway [MEKK2/3 (also known as MAP3K2/3); MEK5 (also known as MAP2K5)], culminating on ERK5 (MAPK7), which associates with MEF2 directly to enhance transcriptional activity. MEF2 activates transcription of the Mmp10 gene, which encodes a matrix metalloproteinase that degrades endothelial cell junctions. HDAC7, which is expressed specifically in the developing endothelium, represses Mmp10 expression via MEF2. In the absence of HDAC7, MMP10 is upregulated and its inhibitor, TIMP1, is downregulated, leading to a loss in vascular integrity.

In addition to endothelial cells, MEF2 has important functions in smooth muscle cells. Whereas endothelial cells differentiate in Mef2c-null embryos, smooth muscle cells fail to properly differentiate (Lin et al., 1998). This function of MEF2 occurs, at least partly, through myocardin, a serum response factor (SRF) and MEF2 transcriptional coactivator that is necessary for smooth muscle differentiation (Wang et al., 2004; Wang et al., 2003). We recently showed that MEF2 recruits a specific isoform of myocardin, which together with MEF2 coactivates the myocardin gene through a positive-feedback loop (Creemers et al., 2006). Interestingly, MEF2 is upregulated in activated smooth muscle cells (Firulli et al., 1996), which suggests that MEF2 functions in the smooth muscle stress response after injury or in pathological states (e.g. artherosclerosis).

Control of neuronal differentiation and survival by MEF2

MEF2 proteins are highly enriched in neurons and exhibit distinct patterns of expression in different regions of the brain, with highest levels being present in the cerebellum, cerebral cortex and hippocampus (Ikeshima et al., 1995; Leifer et al., 1993; Lin et al., 1996; Lyons et al., 1995). MEF2 protects neurons from apoptotic death (Mao et al., 1999; Mao and Wiedmann, 1999; Okamoto et al., 2000), which contrasts with its pro-apoptotic function in thymocytes (Woronicz et al., 1995). The ability of MEF2 to regulate neuronal-specific transcriptional programs may occur through DNA-binding site selection. MEF2 that is expressed in neurons shows optimal DNA-binding constraints for specific nucleotide sequences that flank the MEF2 site, and this is not observed with MEF2 factors from other cell types (Andres et al., 1995).

Recently it was shown that MEF2 proteins regulate dendrite morphogenesis, differentiation of post-synaptic structures (Shalizi et al., 2006) and excitatory synapse number (Flavell et al., 2006). Sumoylation of MEF2A promotes the post-synaptic differentiation of neurons by repressing the expression of the NUR77 transcription factor (Shalizi et al., 2006), a negative regulator of dendritic differentiation (Scheschonka et al., 2007). In addition, dephosphorylation of MEF2 by calcineurin regulates the expression of activity-regulated cytoskeletal-associated protein (Arc) and synaptic RAS GTPase-activating protein (synGAP; also known as Syngap1) (Flavell et al., 2006). ARC and synGAP play important roles in synaptic disassembly by promoting the internalization of glutamate receptors (Flavell et al., 2006) and by inhibiting Ras-MAP signaling (Vazquez et al., 2004), respectively. In response to activity-dependent calcium signaling, calcineurin dephosphorylates MEF2 at Ser408, signaling a switch from the sumoylation to the acetylation of its residue Lys403. This change restricts the numbers of synapses that form (Flavell et al., 2006) and inhibits dendritic claw differentiation (Shalizi et al., 2006) through the activation of the orphan nuclear receptor Nur77 and of Arc and synGAP.

Thus, specific signaling events modulate gene expression by post-translationally modifying MEF2 to control synapse development and plasticity. The functions of individual MEF2 proteins and their roles in synaptic differentiation and disassembly in vivo have yet to be examined. Based on recent literature, however, MEF2 appears to play a role in synaptic plasticity, suggesting an important role for these proteins in learning and memory.

Control of T-cell development by MEF2

The development and activation of thymocytes (T-cells) is a highly regulated process that requires multiple signaling cascades to direct changes in gene expression that alter T-cell state or fate. Calcium signaling pathways play important roles in T-cell selection during development and in T-cell receptor (TCR)-induced apoptosis (Woronicz et al., 1995). NUR77 is a crucial mediator of TCR-induced apoptosis, and TCR-induced expression of NUR77 is mediated through two MEF2 sites in the Nur77 promoter (Youn et al., 1999). In unstimulated T-cells, MEF2 is associated with transcriptional co-repressors, such as HDAC7 and Cabin1, which inhibit Nur77 expression (Dequiedt et al., 2003; Youn and Liu, 2000; Youn et al., 1999).

Following TCR activation, HDAC7 becomes dissociated from MEF2 through nucleocytoplasmic shuttling. Phosphorylation of HDAC7 by PKD1 recruits 14-3-3 and translocates HDAC7 to the cytoplasm, allowing the activation of MEF2 (Parra et al., 2005). Conversely, HDAC7 is dephosphorylated by protein phosphatase 1β (PP1β; also known as PPP1CB) and myosin phosphatase targeting subunit 1 (MYPT1; also known as PPP1R12A), which are components of the myosin phosphatase complex that promote HDAC7 nuclear localization and repression of NUR77 expression (Parra et al., 2007). Therefore, regulation of MEF2 activity by association with transcriptional repressors is highly regulated in T-cells, and demonstrates the importance of MEF2-HDAC signaling in T-cell development, differentiation and thymocyte selection (Kasler and Verdin, 2007).

Conclusion

MEF2 is an ancient mediator of signal-dependent transcription and cell differentiation, and predates most of the transcription factors with which it cooperates to control metazoan development. In virtually every cell type in which its functions have been investigated, MEF2 has been found to serve as a central component of differentiation and development through its ability to potentiate the activities of other regulators, and we speculate that MEF2 will be found to regulate the differentiation of additional cell types, in which its functions have yet to be investigated. In addition to its central role in tissue-specific gene expression and differentiation, MEF2, through its responsiveness to upstream signaling pathways and through its association with other signal-dependent activators and repressors, such as class II HDACs, also serves as a key intermediary in the transmission of extracellular signals to the genome. This function brings signal-dependence to its downstream programs of gene expression. How MEF2 engages its myriad partner proteins in different cell types to activate different and often opposing programs of gene expression, and why such a diversity of cell types and gene programs evolved with a reliance on MEF2, are interesting questions for the future.

Understanding the mechanism of action of MEF2 has provided not only a window into the logic of development, but has also revealed basic mechanisms of numerous diseases. Armed with these insights, it should be possible to modulate complex developmental and disease phenotypes through the manipulation of MEF2 activity.

Acknowledgments

We thank Jennifer Brown for assistance with manuscript preparation and Alisha Tizenor for graphic design.

  • © 2007.

References

  1. ↵
    Andres, V., Cervera, M. and Mahdavi, V. (1995). Determination of the consensus binding site for MEF2 expressed in muscle and brain reveals tissue-specific sequence constraints. J. Biol. Chem. 270,23246 -23249.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Arnold, M. A., Kim, Y., Czubryt, M. P., Phan, D., McAnally, J., Qi, X., Shelton, J. M., Richardson, J. A., Bassel-Duby, R. and Olson, E. N. (2007). MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev. Cell 12,377 -389.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Bassel-Duby, R., Hernandez, M. D., Gonzalez, M. A., Krueger, J. K. and Williams, R. S. (1992). A 40-kilodalton protein binds specifically to an upstream sequence element essential for muscle-specific transcription of the human myoglobin promoter. Mol. Cell. Biol. 12,5024 -5032.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Berdeaux, R., Goebel, N., Banaszynski, L., Takemori, H., Wandless, T., Shelton, G. D. and Montminy, M. (2007). SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat. Med. 13,597 -603.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Bertos, N. R., Wang, A. H. and Yang, X. J. (2001). Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 79,243 -252.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Black, B. L. (2007). Transcriptional pathways in second heart field development. Semin. Cell Dev. Biol. 18,67 -76.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Black, B. L. and Olson, E. N. (1998). Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu. Rev. Cell Dev. Biol. 14,167 -196.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Black, B. L., Lu, J. and Olson, E. N. (1997). The MEF2A 3′ untranslated region functions as a cis-acting translational repressor. Mol. Cell. Biol. 17,2756 -2763.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Bour, B. A., O'Brien, M. A., Lockwood, W. L., Goldstein, E. S., Bodmer, R., Taghert, P. H., Abmayr, S. M. and Nguyen, H. T. (1995). Drosophila MEF2, a transcription factor that is essential for myogenesis. Genes Dev. 9, 730-741.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Boutz, P. L., Chawla, G., Stoilov, P. and Black, D. L. (2007). MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development. Genes Dev. 21,71 -84.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Bruder, S. P. and Caplan, A. I. (1989). Cellular and molecular events during embryonic bone development. Connect. Tissue Res. 20,65 -71.
    OpenUrlPubMed
  12. ↵
    Cai, C. L., Liang, X., Shi, Y., Chu, P. H., Pfaff, S. L., Chen, J. and Evans, S. (2003). Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev. Cell 5, 877-889.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Chang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A. and Olson, E. N. (2004). Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 24,8467 -8476.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A. and Olson, E. N. (2006). Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126,321 -334.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Charitè, J., McFadden, D. G., Merlo, G., Levi, G., Clouthier, D. E., Yanagisawa, M., Richardson, J. A. and Olson, E. N. (2001). Role of Dlx6 in regulation of an endothelin-1-dependent, dHAND branchial arch enhancer. Genes Dev. 15,3039 -3049.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M., Conlon, F. L. and Wang, D. Z. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38,228 -233.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Cheng, T. C., Wallace, M. C., Merlie, J. P. and Olson, E. N. (1993). Separable regulatory elements governing myogenin transcription in mouse embryogenesis. Science 261,215 -218.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Clouthier, D. E., Hosoda, K., Richardson, J. A., Williams, S. C., Yanagisawa, H., Kuwaki, T., Kumada, M., Hammer, R. E. and Yanagisawa, M. (1998). Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 125,813 -824.
    OpenUrlAbstract
  19. ↵
    Clouthier, D. E., Williams, S. C., Yanagisawa, H., Wieduwilt, M., Richardson, J. A. and Yanagisawa, M. (2000). Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor-deficient mice. Dev. Biol. 217, 10-24.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Creemers, E. E., Sutherland, L. B., McAnally, J., Richardson, J. A. and Olson, E. N. (2006). Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. Development 133,4245 -4256.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Cripps, R. M. and Olson, E. N. (1998). Twist is required for muscle template splitting during adult Drosophila myogenesis. Dev. Biol. 203,106 -115.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Cripps, R. M., Black, B. L., Zhao, B., Lien, C. L., Schulz, R. A. and Olson, E. N. (1998). The myogenic regulatory gene Mef2 is a direct target for transcriptional activation by Twist during Drosophila myogenesis. Genes Dev. 12,422 -434.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Cripps, R. M., Lovato, T. L. and Olson, E. N. (2004). Positive autoregulation of the Myocyte enhancer factor-2 myogenic control gene during somatic muscle development in Drosophila. Dev. Biol. 267,536 -547.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. and van Kuilenburg, A. B. (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370,737 -749.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    De Val, S., Anderson, J. P., Heidt, A. B., Khiem, D., Xu, S. M. and Black, B. L. (2004). Mef2c is activated directly by Ets transcription factors through an evolutionarily conserved endothelial cell-specific enhancer. Dev. Biol. 275,424 -434.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    Dequiedt, F., Kasler, H., Fischle, W., Kiermer, V., Weinstein, M., Herndier, B. G. and Verdin, E. (2003). HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 18,687 -698.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Dodou, E. and Treisman, R. (1997). The Saccharomyces cerevisiae MADS-box transcription factor Rlm1 is a target for the Mpk1 mitogen-activated protein kinase pathway. Mol. Cell. Biol. 17,1848 -1859.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Dodou, E., Verzi, M. P., Anderson, J. P., Xu, S. M. and Black, B. L. (2004). Mef2c is a direct transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse embryonic development. Development 131,3931 -3942.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Duan, H., Skeath, J. B. and Nguyen, H. T. (2001). Drosophila Lame duck, a novel member of the Gli superfamily, acts as a key regulator of myogenesis by controlling fusion-competent myoblast development. Development 128,4489 -4500.
    OpenUrlPubMed
  30. ↵
    Edmondson, D. G., Cheng, T. C., Cserjesi, P., Chakraborty, T. and Olson, E. N. (1992). Analysis of the myogenin promoter reveals an indirect pathway for positive autoregulation mediated by the muscle-specific enhancer factor MEF-2. Mol. Cell. Biol. 12,3665 -3677.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Edmondson, D. G., Lyons, G. E., Martin, J. F. and Olson, E. N. (1994). Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development 120,1251 -1263.
    OpenUrlAbstract
  32. ↵
    Fickett, J. W. (1996). Quantitative discrimination of MEF2 sites. Mol. Cell. Biol. 16,437 -441.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Firulli, A. B., Miano, J. M., Bi, W., Johnson, A. D., Casscells, W., Olson, E. N. and Schwarz, J. J. (1996). Myocyte enhancer binding factor-2 expression and activity in vascular smooth muscle cells. Association with the activated phenotype. Circ. Res. 78,196 -204.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Flavell, S. W., Cowan, C. W., Kim, T. K., Greer, P. L., Lin, Y., Paradis, S., Griffith, E. C., Hu, L. S., Chen, C. and Greenberg, M. E. (2006). Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 311,1008 -1012.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Gajewski, K., Kim, Y., Lee, Y. M., Olson, E. N. and Schulz, R. A. (1997). D-mef2 is a target for Tinman activation during Drosophila heart development. EMBO J. 16,515 -522.
    OpenUrlAbstract
  36. ↵
    Gajewski, K., Kim, Y., Choi, C. Y. and Schulz, R. A. (1998). Combinatorial control of Drosophila mef2 gene expression in cardiac and somatic muscle cell lineages. Dev. Genes Evol. 208,382 -392.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    Gossett, L. A., Kelvin, D. J., Sternberg, E. A. and Olson, E. N. (1989). A new myocyte-specific enhancer-binding factor that recognizes a conserved element associated with multiple muscle-specific genes. Mol. Cell. Biol. 9,5022 -5033.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Gottlieb, P. D., Pierce, S. A., Sims, R. J., Yamagishi, H., Weihe, E. K., Harriss, J. V., Maika, S. D., Kuziel, W. A., King, H. L., Olson, E. N. et al. (2002). Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat. Genet. 31, 25-32.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Haberland, M., Arnold, M. A., McAnally, J., Phan, D., Kim, Y. and Olson, E. N. (2007). Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol. Cell. Biol. 27,518 -525.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Hall, B. K. and Miyake, T. (1995). Divide, accumulate, differentiate: cell condensation in skeletal development revisited. Int. J. Dev. Biol. 39,881 -893.
    OpenUrlPubMedWeb of Science
  41. ↵
    Han, J., Jiang, Y., Li, Z., Kravchenko, V. V. and Ulevitch, R. J. (1997). Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386,296 -299.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    Hayashi, M., Kim, S. W., Imanaka-Yoshida, K., Yoshida, T., Abel, E. D., Eliceiri, B., Yang, Y., Ulevitch, R. J. and Lee, J. D. (2004). Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J. Clin. Invest. 113,1138 -1148.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    He, L. and Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5,522 -531.
    OpenUrlCrossRefPubMed
  44. ↵
    Hinits, Y. and Hughes, S. M. (2007). Mef2s are required for thick filament formation in nascent muscle fibres. Development 134,2511 -2519.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Ikeshima, H., Imai, S., Shimoda, K., Hata, J. and Takano, T. (1995). Expression of a MADS box gene, MEF2D, in neurons of the mouse central nervous system: implication of its binary function in myogenic and neurogenic cell lineages. Neurosci. Lett. 200,117 -120.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    Junion, G., Jagla, T., Duplant, S., Tapin, R., Da Ponte, J. P. and Jagla, K. (2005). Mapping Dmef2-binding regulatory modules by using a ChIP-enriched in silico targets approach. Proc. Natl. Acad. Sci. USA 102,18479 -18484.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Karamboulas, C., Dakubo, G. D., Liu, J., De Repentigny, Y., Yutzey, K., Wallace, V. A., Kothary, R. and Skerjanc, I. S. (2006). Disruption of MEF2 activity in cardiomyoblasts inhibits cardiomyogenesis. J. Cell Sci. 119,4315 -4321.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Karaplis, A. C., Luz, A., Glowacki, J., Bronson, R. T., Tybulewicz, V. L., Kronenberg, H. M. and Mulligan, R. C. (1994). Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev. 8, 277-289.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Kasler, H. G. and Verdin, E. (2007). Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol. Cell. Biol. 27,5184 -5200.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Kato, Y., Kravchenko, V. V., Tapping, R. I., Han, J., Ulevitch, R. J. and Lee, J. D. (1997). BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 16,7054 -7066.
    OpenUrlAbstract
  51. ↵
    Kim, H. K., Lee, Y. S., Sivaprasad, U., Malhotra, A. and Dutta, A. (2006). Muscle-specific microRNA miR-206 promotes muscle differentiation. J. Cell Biol. 174,677 -687.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Knecht, A. K. and Bronner-Fraser, M. (2002). Induction of the neural crest: a multigene process. Nat. Rev. Genet. 3,453 -461.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    Kurihara, Y., Kurihara, H., Suzuki, H., Kodama, T., Maemura, K., Nagai, R., Oda, H., Kuwaki, T., Cao, W. H., Kamada, N. et al. (1994). Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368,703 -710.
    OpenUrlCrossRefPubMed
  54. ↵
    Lanske, B., Karaplis, A. C., Lee, K., Luz, A., Vortkamp, A., Pirro, A., Karperien, M., Defize, L. H., Ho, C., Mulligan, R. C. et al. (1996). PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273,663 -666.
    OpenUrlAbstract
  55. ↵
    Leifer, D., Krainc, D., Yu, Y. T., McDermott, J., Breitbart, R. E., Heng, J., Neve, R. L., Kosofsky, B., Nadal-Ginard, B. and Lipton, S. A. (1993). MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc. Natl. Acad. Sci. USA 90,1546 -1550.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Lilly, B., Zhao, B., Ranganayakulu, G., Paterson, B. M., Schulz, R. A. and Olson, E. N. (1995). Requirement of MADS domain transcription factor D-MEF2 for muscle formation in Drosophila. Science 267,688 -693.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Lin, M. H., Bour, B. A., Abmayr, S. M. and Storti, R. V. (1997). Ectopic expression of MEF2 in the epidermis induces epidermal expression of muscle genes and abnormal muscle development in Drosophila. Dev. Biol. 182,240 -255.
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    Lin, S. C., Lin, M. H., Horvath, P., Reddy, K. L. and Storti, R. V. (1997). PDP1, a novel Drosophila PAR domain bZIP transcription factor expressed in developing mesoderm, endoderm and ectoderm, is a transcriptional regulator of somatic muscle genes. Development 124,4685 -4696.
    OpenUrlAbstract
  59. ↵
    Lin, Q., Schwarz, J., Bucana, C. and Olson, E. N. (1997). Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276,1404 -1407.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Lin, Q., Lu, J., Yanagisawa, H., Webb, R., Lyons, G. E., Richardson, J. A. and Olson, E. N. (1998). Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 125,4565 -4574.
    OpenUrlAbstract
  61. ↵
    Lin, X., Shah, S. and Bulleit, R. F. (1996). The expression of MEF2 genes is implicated in CNS neuronal differentiation. Brain Res. Mol. Brain Res. 42,307 -316.
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    Lu, J., McKinsey, T. A., Zhang, C. L. and Olson, E. N. (2000). Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol. Cell 6,233 -244.
    OpenUrlCrossRefPubMedWeb of Science
  63. ↵
    Lyons, G. E., Micales, B. K., Schwarz, J., Martin, J. F. and Olson, E. N. (1995). Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J. Neurosci. 15,5727 -5738.
    OpenUrlAbstract
  64. ↵
    Malik, S., Huang, C. F. and Schmidt, J. (1995). The role of the CANNTG promoter element (E box) and the myocyte-enhancer-binding-factor-2 (MEF-2) site in the transcriptional regulation of the chick myogenin gene. Eur. J. Biochem. 230,88 -96.
    OpenUrlPubMedWeb of Science
  65. ↵
    Mao, Z. and Wiedmann, M. (1999). Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. J. Biol. Chem. 274,31102 -31107.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M. and Greenberg, M. E. (1999). Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286,785 -790.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    Martin, J. F., Schwarz, J. J. and Olson, E. N. (1993). Myocyte enhancer factor (MEF) 2C: a tissue-restricted member of the MEF-2 family of transcription factors. Proc. Natl. Acad. Sci. USA 90,5282 -5286.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Martin, J. F., Miano, J. M., Hustad, C. M., Copeland, N. G., Jenkins, N. A. and Olson, E. N. (1994). A Mef2 gene that generates a muscle-specific isoform via alternative mRNA splicing. Mol. Cell. Biol. 14,1647 -1656.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    McDermott, J. C., Cardoso, M. C., Yu, Y. T., Andres, V., Leifer, D., Krainc, D., Lipton, S. A. and Nadal-Ginard, B. (1993). hMEF2C gene encodes skeletal muscle- and brain-specific transcription factors. Mol. Cell. Biol. 13,2564 -2577.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    McKinsey, T. A. and Olson, E. N. (2005). Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Invest. 115,538 -546.
    OpenUrlCrossRefPubMedWeb of Science
  71. ↵
    McKinsey, T. A., Zhang, C. L. and Olson, E. N. (2001). Control of muscle development by dueling HATs and HDACs. Curr. Opin. Genet. Dev. 11,497 -504.
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    McKinsey, T. A., Zhang, C. L. and Olson, E. N. (2002a). MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27, 40-47.
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    McKinsey, T. A., Zhang, C. L. and Olson, E. N. (2002b). Signaling chromatin to make muscle. Curr. Opin. Cell Biol. 14,763 -772.
    OpenUrlCrossRefPubMedWeb of Science
  74. ↵
    Miller, C. T., Swartz, M. E., Khuu, P. A., Walker, M. B., Eberhart, J. K. and Kimmel, C. B. (2007). mef2ca is required in cranial neural crest to effect Endothelin1 signaling in zebrafish. Dev. Biol. 308,144 -157.
    OpenUrlCrossRefPubMedWeb of Science
  75. ↵
    Molkentin, J. D. and Olson, E. N. (1996). Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc. Natl. Acad. Sci. USA 93,9366 -9373.
    OpenUrlAbstract/FREE Full Text
  76. ↵
    Molkentin, J. D., Black, B. L., Martin, J. F. and Olson, E. N. (1995). Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell 83,1125 -1136.
    OpenUrlCrossRefPubMedWeb of Science
  77. ↵
    Naya, F. J., Black, B. L., Wu, H., Bassel-Duby, R., Richardson, J. A., Hill, J. A. and Olson, E. N. (2002). Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat. Med. 8,1303 -1309.
    OpenUrlCrossRefPubMedWeb of Science
  78. ↵
    Nguyen, H. T. and Xu, X. (1998). Drosophila mef2 expression during mesoderm development is controlled by a complex array of cis-acting regulatory modules. Dev. Biol. 204,550 -566.
    OpenUrlCrossRefPubMedWeb of Science
  79. ↵
    Okamoto, S., Krainc, D., Sherman, K. and Lipton, S. A. (2000). Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc. Natl. Acad. Sci. USA 97,7561 -7566.
    OpenUrlAbstract/FREE Full Text
  80. ↵
    Olson, E. N. (2004). Undermining the endothelium by ablation of MAPK-MEF2 signaling. J. Clin. Invest. 113,1110 -1112.
    OpenUrlCrossRefPubMedWeb of Science
  81. ↵
    Parra, M., Kasler, H., McKinsey, T. A., Olson, E. N. and Verdin, E. (2005). Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J. Biol. Chem. 280,13762 -13770.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    Parra, M., Mahmoudi, T. and Verdin, E. (2007). Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes. Genes Dev. 21,638 -643.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    Patan, S. (2000). Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J. Neurooncol. 50, 1-15.
    OpenUrlCrossRefPubMed
  84. ↵
    Phan, D., Rasmussen, T. L., Nakagawa, O., McAnally, J., Gottlieb, P. D., Tucker, P. W., Richardson, J. A., Bassel-Duby, R. and Olson, E. N. (2005). BOP, a regulator of right ventricular heart development, is a direct transcriptional target of MEF2C in the developing heart. Development 132,2669 -2678.
    OpenUrlAbstract/FREE Full Text
  85. ↵
    Pi, X., Yan, C. and Berk, B. C. (2004). Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ. Res. 94,362 -369.
    OpenUrlAbstract/FREE Full Text
  86. ↵
    Pollock, R. and Treisman, R. (1991). Human SRF-related proteins: DNA-binding properties and potential regulatory targets. Genes Dev. 5,2327 -2341.
    OpenUrlAbstract/FREE Full Text
  87. ↵
    Potthoff, M. J., Arnold, M. A., McAnally, J., Richardson, J. A., Bassel-Duby, R. and Olson, E. N. (2007a). Regulation of skeletal muscle sarcomere assembly and postnatal muscle function by Mef2c. Mol. Cell. Biol. 27 (in press).
  88. ↵
    Potthoff, M. J., Wu, H., Arnold, M. A., Shelton, J. M., Backs, J., McAnally, J., Richardson, J. A., Bassel-Duby, R. and Olson, E. N. (2007b). Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J. Clin. Invest. 117,2459 -2467.
    OpenUrlCrossRefPubMedWeb of Science
  89. ↵
    Prokop, A., Landgraf, M., Rushton, E., Broadie, K. and Bate, M. (1996). Presynaptic development at the Drosophila neuromuscular junction: assembly and localization of presynaptic active zones. Neuron 17,617 -626.
    OpenUrlCrossRefPubMedWeb of Science
  90. ↵
    Ranganayakulu, G., Zhao, B., Dokidis, A., Molkentin, J. D., Olson, E. N. and Schulz, R. A. (1995). A series of mutations in the D-MEF2 transcription factor reveal multiple functions in larval and adult myogenesis in Drosophila. Dev. Biol. 171,169 -181.
    OpenUrlCrossRefPubMedWeb of Science
  91. ↵
    Rao, P. K., Kumar, R. M., Farkhondeh, M., Baskerville, S. and Lodish, H. F. (2006). Myogenic factors that regulate expression of muscle-specific microRNAs. Proc. Natl. Acad. Sci. USA 103,8721 -8726.
    OpenUrlAbstract/FREE Full Text
  92. ↵
    Ruiz-Gomez, M., Coutts, N., Suster, M. L., Landgraf, M. and Bate, M. (2002). myoblasts incompetent encodes a zinc finger transcription factor required to specify fusion-competent myoblasts in Drosophila. Development 129,133 -141.
    OpenUrlAbstract/FREE Full Text
  93. ↵
    Sandmann, T., Jensen, L. J., Jakobsen, J. S., Karzynski, M. M., Eichenlaub, M. P., Bork, P. and Furlong, E. E. (2006). A temporal map of transcription factor activity: mef2 directly regulates target genes at all stages of muscle development. Dev. Cell 10,797 -807.
    OpenUrlCrossRefPubMedWeb of Science
  94. ↵
    Sandmann, T., Girardot, C., Brehme, M., Tongprasit, W., Stolc, V. and Furlong, E. E. (2007). A core transcriptional network for early mesoderm development in Drosophila melanogaster. Genes Dev. 21,436 -449.
    OpenUrlAbstract/FREE Full Text
  95. ↵
    Scheschonka, A., Tang, Z. and Betz, H. (2007). Sumoylation in neurons: nuclear and synaptic roles? Trends Neurosci. 30,85 -91.
    OpenUrlCrossRefPubMedWeb of Science
  96. ↵
    Shalizi, A., Gaudilliere, B., Yuan, Z., Stegmuller, J., Shirogane, T., Ge, Q., Tan, Y., Schulman, B., Harper, J. W. and Bonni, A. (2006). A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311,1012 -1017.
    OpenUrlAbstract/FREE Full Text
  97. ↵
    Shen, H., McElhinny, A. S., Cao, Y., Gao, P., Liu, J., Bronson, R., Griffin, J. D. and Wu, L. (2006). The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev. 20,675 -688.
    OpenUrlAbstract/FREE Full Text
  98. ↵
    Shore, P. and Sharrocks, A. D. (1995). The MADS-box family of transcription factors. Eur. J. Biochem. 229,1 -13.
    OpenUrlCrossRefPubMedWeb of Science
  99. ↵
    Simpson, P. (1983). Maternal-zygotic gene interactions during formation of the dorsoventral pattern in drosophila embryos. Genetics 105,615 -632.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    Sokol, N. S. and Ambros, V. (2005). Mesodermally expressed Drosophila microRNA-1 is regulated by Twist and is required in muscles during larval growth. Genes Dev. 19,2343 -2354.
    OpenUrlAbstract/FREE Full Text
  101. ↵
    St-Jacques, B., Hammerschmidt, M. and McMahon, A. P. (1999). Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13,2072 -2086.
    OpenUrlAbstract/FREE Full Text
  102. ↵
    Tapscott, S. J. (2005). The circuitry of a master switch: Myod and the regulation of skeletal muscle gene transcription. Development 132,2685 -2695.
    OpenUrlAbstract/FREE Full Text
  103. ↵
    Taylor, M. V. (2000). A novel Drosophila, mef2-regulated muscle gene isolated in a subtractive hybridization-based molecular screen using small amounts of zygotic mutant RNA. Dev. Biol. 220,37 -52.
    OpenUrlCrossRefPubMedWeb of Science
  104. ↵
    Thomas, T., Kurihara, H., Yamagishi, H., Kurihara, Y., Yazaki, Y., Olson, E. N. and Srivastava, D. (1998). A signaling cascade involving endothelin-1, dHAND and msx1 regulates development of neural-crest-derived branchial arch mesenchyme. Development 125,3005 -3014.
    OpenUrlAbstract
  105. ↵
    Trainor, P. A. (2005). Specification of neural crest cell formation and migration in mouse embryos. Semin. Cell Dev. Biol. 16,683 -693.
    OpenUrlCrossRefPubMedWeb of Science
  106. ↵
    Vazquez, L. E., Chen, H. J., Sokolova, I., Knuesel, I. and Kennedy, M. B. (2004). SynGAP regulates spine formation. J. Neurosci. 24,8862 -8872.
    OpenUrlAbstract/FREE Full Text
  107. ↵
    Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A. et al. (2004). Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119,555 -566.
    OpenUrlCrossRefPubMedWeb of Science
  108. ↵
    Verzi, M. P., Agarwal, P., Brown, C., McCulley, D. J., Schwarz, J. J. and Black, B. L. (2007). The transcription factor MEF2C is required for craniofacial development. Dev. Cell 12,645 -652.
    OpenUrlCrossRefPubMedWeb of Science
  109. ↵
    von Both, I., Silvestri, C., Erdemir, T., Lickert, H., Walls, J. R., Henkelman, R. M., Rossant, J., Harvey, R. P., Attisano, L. and Wrana, J. L. (2004). Foxh1 is essential for development of the anterior heart field. Dev. Cell 7, 331-345.
    OpenUrlCrossRefPubMedWeb of Science
  110. ↵
    Vong, L. H., Ragusa, M. J. and Schwarz, J. J. (2005). Generation of conditional Mef2cloxP/loxP mice for temporal- and tissue-specific analyses. Genesis 43, 43-48.
    OpenUrlPubMed
  111. ↵
    Vortkamp, A., Lee, K., Lanske, B., Segre, G. V., Kronenberg, H. M. and Tabin, C. J. (1996). Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273,613 -622.
    OpenUrlAbstract
  112. ↵
    Wang, D. Z., Valdez, M. R., McAnally, J., Richardson, J. and Olson, E. N. (2001). The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins during skeletal muscle development. Development 128,4623 -4633.
    OpenUrlPubMedWeb of Science
  113. ↵
    Wang, Z., Wang, D. Z., Pipes, G. C. and Olson, E. N. (2003). Myocardin is a master regulator of smooth muscle gene expression. Proc. Natl. Acad. Sci. USA 100,7129 -7134.
    OpenUrlAbstract/FREE Full Text
  114. ↵
    Wang, Z., Wang, D. Z., Hockemeyer, D., McAnally, J., Nordheim, A. and Olson, E. N. (2004). Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 428,185 -189.
    OpenUrlCrossRefPubMedWeb of Science
  115. ↵
    Weir, E. C., Philbrick, W. M., Amling, M., Neff, L. A., Baron, R. and Broadus, A. E. (1996). Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc. Natl. Acad. Sci. USA 93,10240 -10245.
    OpenUrlAbstract/FREE Full Text
  116. ↵
    Woronicz, J. D., Lina, A., Calnan, B. J., Szychowski, S., Cheng, L. and Winoto, A. (1995). Regulation of the Nur77 orphan steroid receptor in activation-induced apoptosis. Mol. Cell. Biol. 15,6364 -6376.
    OpenUrlAbstract/FREE Full Text
  117. ↵
    Yang, C. C., Ornatsky, O. I., McDermott, J. C., Cruz, T. F. and Prody, C. A. (1998). Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1. Nucleic Acids Res. 26,4771 -4777.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    Yee, S. P. and Rigby, P. W. (1993). The regulation of myogenin gene expression during the embryonic development of the mouse. Genes Dev. 7,1277 -1289.
    OpenUrlAbstract/FREE Full Text
  119. ↵
    Youn, H. D. and Liu, J. O. (2000). Cabin1 represses MEF2-dependent Nur77 expression and T cell apoptosis by controlling association of histone deacetylases and acetylases with MEF2. Immunity 13,85 -94.
    OpenUrlCrossRefPubMedWeb of Science
  120. ↵
    Youn, H. D., Sun, L., Prywes, R. and Liu, J. O. (1999). Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2. Science 286,790 -793.
    OpenUrlAbstract/FREE Full Text
  121. ↵
    Yu, Y. T., Breitbart, R. E., Smoot, L. B., Lee, Y., Mahdavi, V. and Nadal-Ginard, B. (1992). Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. Genes Dev. 6,1783 -1798.
    OpenUrlAbstract/FREE Full Text
  122. ↵
    Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A. and Olson, E. N. (2002). Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110,479 -488.
    OpenUrlCrossRefPubMedWeb of Science
  123. ↵
    Zhao, Y., Samal, E. and Srivastava, D. (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436,214 -220.
    OpenUrlCrossRefPubMedWeb of Science
Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

 Download PDF

Email

Thank you for your interest in spreading the word on Development.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MEF2: a central regulator of diverse developmental programs
(Your Name) has sent you a message from Development
(Your Name) thought you would like to see the Development web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Review
MEF2: a central regulator of diverse developmental programs
Matthew J. Potthoff, Eric N. Olson
Development 2007 134: 4131-4140; doi: 10.1242/dev.008367
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Review
MEF2: a central regulator of diverse developmental programs
Matthew J. Potthoff, Eric N. Olson
Development 2007 134: 4131-4140; doi: 10.1242/dev.008367

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • Summary
    • Introduction
    • The MEF2 family
    • Signaling to MEF2
    • MEF2: a central regulator of Drosophila myogenesis
    • MEF2 control of vertebrate skeletal muscle differentiation
    • Control of vertebrate heart development by MEF2
    • Control of neural crest development by MEF2
    • Control of bone development by MEF2
    • Control of vascular integrity by MEF2
    • Control of neuronal differentiation and survival by MEF2
    • Control of T-cell development by MEF2
    • Conclusion
    • Acknowledgments
    • References
  • Figures & tables
  • Info & metrics
  • PDF

Related articles

Cited by...

More in this TOC section

  • The ECM as a driver of heart development and repair
  • Dynamic properties of mitochondria during human corticogenesis
  • Understanding axial progenitor biology in vivo and in vitro
Show more REVIEW

Similar articles

Other journals from The Company of Biologists

Journal of Cell Science

Journal of Experimental Biology

Disease Models & Mechanisms

Biology Open

Advertisement

A new society for regenerative biologists

Kenneth Poss and Elly Tanaka announce the launch of the International Society for Regenerative Biology (ISRB), which will promote research and education in the field of regenerative biology.


Upcoming special issue: call for papers

The Immune System in Development and Regeneration
Guest editors: Florent Ginhoux and Paul Martin
Submission deadline: 1 September 2021
Publication: Spring 2022

The special issue welcomes Review articles as well as Research articles, and will be widely promoted online and at key global conferences.


An interview with Cagney Coomer

Over a virtual chat, we spoke to Cagney Coomer about her experiences in the lab, the classroom and the community centre, and why she thinks outreach and role models are vital to science.


Development presents...

Our successful webinar series continues into 2021, with early-career researchers presenting their papers and a chance to virtually network with the developmental biology community afterwards. Here, Michèle Romanos talks about her new preprint, which mixes experimentation in quail embryos and computational modelling to understand how heterogeneity in a tissue influences cell rate.

Save your spot at our next session:

10 March
Time: 9:00 (GMT)
Chaired by: Thomas Lecuit

Join our mailing list to receive news and updates on the series.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Special issues
  • Subject collections
  • Sign up for alerts

About us

  • About Development
  • About the Node
  • Editors and board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Journal Meetings
  • Workshops
  • The Company of Biologists

For authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • Biology Open transfer

Journal info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Sign up for alerts

Contact

  • Contact Development
  • Subscriptions
  • Advertising
  • Feedback
  • Institutional usage stats (logged-in users only)

 Twitter   YouTube   LinkedIn

© 2021   The Company of Biologists Ltd   Registered Charity 277992